Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer

Table 4

Distribution of XRCC3 Thr241Met, XRCC4 G(‐1394) T, Bax G(-248) A, and BCL2 C(‐938) A genotypes among the controls and patients.

Genotype/allele	Controls, (%)	Patients, (%)	value	OR (95% CI)
Bax G(-248)A
GG	80 (51)	92 (53)		Reference
GA	74 (47)	58 (33)	0.12	0.68 (0.42–1.10)
AA	4 (3)	25 (14)	0.002	5.43 (1.70–15.84)
G allele frequency	0,74	0,69		Reference
A allele frequency	0,36	0,31	0.90	0.92 (0.50–1.72)
BCL2 C(–938)A
CC	33 (21)	52 (30)		Reference
CA	76 (48)	68 (39)	0.06	0.56 (0.31–1.01)
AA	49 (31)	55 (31)	0.32	0.71 (0.38–1.32)
C allele frequency	0,45	0,49		Reference
A allele frequency	0,55	0,51	0.67	0.85 (0.47–1.54)
XRCC3 Thr241Met
Thr/Thr (CC)	61 (39)	52 (30)		Reference
Thr/Met (CT)	83 (52)	90 (51)	0.38	1.27 (0.77–2.10)
Met/Met (TT)	14 (9)	33 (19)	0.009	2.77 (1.26–6.11)
Thr allele frequency	0,65	0,55		Reference
Met allele frequency	0,35	0,45	0.19	1.51 (0.82–2.79)
XRCC4 G(‐1394)T
GG	24 (15)	32 (18)		Reference
GT	66 (42)	93 (53)	0.98	1.05 (0.55–2.05)
TT	68 (43)	50 (29)	0.10	0.55 (0.28–1.10)
G allele frequency	0,36	0,45		Reference
T allele frequency	0,64	0,55	0.25	0.68 (0.37–1.26)